Charmacy Pharmaceutical Co., Ltd. (Stock Code: 2289) unveiled a plan to discontinue its Board of Supervisors, subject to shareholder approval at an upcoming extraordinary general meeting. According to the announcement dated 20 October 2025, the supervisory functions under the People’s Republic of China Company Law would be absorbed by the Audit Committee of the company’s Board of Directors. Once approved, current Supervisors’ positions and the relevant procedures will be dissolved.

Alongside this proposed change, the company intends to amend its Articles of Association and related internal governance policies. All references to “Supervisors” and the “Board of Supervisors” will be removed, and certain supervisory powers will be reassigned to the Audit Committee. The amendments shall take effect once shareholders vote in favor of the resolution at the extraordinary general meeting.

Charmacy Pharmaceutical Co., Ltd. plans to distribute a circular to shareholders detailing the proposed abolishment of the Board of Supervisors and corresponding updates to the Articles of Association as well as related policies. These measures aim to align the company’s governance structure with the most recent legal and regulatory requirements.